The role of aryl hydrocarbon receptor agonists in the treatment of vitiligo.
AhR
Antioxidation
Melanogenesis
Repigmentation
Tapinarof
Vitiligo
Journal
Archives of dermatological research
ISSN: 1432-069X
Titre abrégé: Arch Dermatol Res
Pays: Germany
ID NLM: 8000462
Informations de publication
Date de publication:
05 Oct 2024
05 Oct 2024
Historique:
received:
30
08
2024
accepted:
14
09
2024
revised:
01
09
2024
medline:
6
10
2024
pubmed:
6
10
2024
entrez:
5
10
2024
Statut:
epublish
Résumé
Vitiligo is a chronic autoimmune disorder characterized by progressive skin depigmentation. Vitiligo significantly impacts patients' quality of life, contributing to psychological and social burdens. Despite readily available therapeutic options, many cases remain refractory to treatment, highlighting the critical need for safer and more effective therapies. Currently, ruxolitinib is the only FDA-approved medication for vitiligo; however, it carries a black box warning for serious adverse effects, including infections, malignancy, and major cardiovascular events, limiting its use. Recent studies have identified the aryl hydrocarbon receptor (AhR) as a promising therapeutic target, suggesting that AhR agonists could address the multifaceted pathogenesis of vitiligo. Adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we conducted a comprehensive search to analyze the role of AhR agonists in the treatment of vitiligo on PubMed, Cochrane, Embase, MEDLINE, and Web of Science databases on April 15, 2024. Fourteen studies met the inclusion criteria, comprising two clinical trials, two case reports, and nine basic science studies. Our search revealed that culturing AhR agonists with melanocytes upregulates melanin-synthesizing enzymes, reduces reactive oxygen species, and modulates pro-inflammatory cytokines such as IL-17A and IL-22. Tapinarof, a topical AhR agonist used commonly for the treatment of psoriasis, demonstrated clinical efficacy in repigmentation with a favorable safety profile compared to long-term steroid use. Although limited by the number of clinical studies, this review underscores the potential of using AhR agonists, such as tapinarof, as a transformative approach to vitiligo management. Future clinical trials are necessary to evaluate the safety, efficacy, and long-term outcomes of AhR agonists.
Identifiants
pubmed: 39369105
doi: 10.1007/s00403-024-03405-2
pii: 10.1007/s00403-024-03405-2
doi:
Substances chimiques
Receptors, Aryl Hydrocarbon
0
Nitriles
0
ruxolitinib
82S8X8XX8H
Pyrazoles
0
AHR protein, human
0
Pyrimidines
0
Basic Helix-Loop-Helix Transcription Factors
0
Types de publication
Journal Article
Systematic Review
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
659Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Bergqvist C, Ezzedine K (2020) Vitiligo: a review. Dermatology 236(6):571–592
doi: 10.1159/000506103
pubmed: 32155629
Frisoli ML, Essien K, Harris JE (2020) Vitiligo: mechanisms of Pathogenesis and treatment. Annu Rev Immunol 38:621–648
doi: 10.1146/annurev-immunol-100919-023531
pubmed: 32017656
Bibeau K et al (2023) Mental Health and Psychosocial Quality-of-life Burden among patients with Vitiligo: findings from the global VALIANT study. JAMA Dermatol 159(10):1124–1128
doi: 10.1001/jamadermatol.2023.2787
pubmed: 37647073
pmcid: 10469285
Seneschal J (2023) Clinical features of Vitiligo and Social Impact on Quality of Life. Dermatol Pract Concept, 13(4s2)
Alikhan A et al (2011) Vitiligo: a comprehensive overview part I. introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol 65(3):473–491
doi: 10.1016/j.jaad.2010.11.061
pubmed: 21839315
Gandhi K et al (2022) Prevalence of Vitiligo among adults in the United States. JAMA Dermatol 158(1):43–50
doi: 10.1001/jamadermatol.2021.4724
pubmed: 34787670
Chen J, Li S, Li C (2021) Mechanisms of melanocyte death in vitiligo. Med Res Rev 41(2):1138–1166
doi: 10.1002/med.21754
pubmed: 33200838
Białczyk A et al (2023) Oxidative stress and potential antioxidant therapies in Vitiligo: a narrative review. Mol Diagn Ther 27(6):723–739
doi: 10.1007/s40291-023-00672-z
pubmed: 37737953
pmcid: 10590312
Opzelura (ruxolitinib) cream, for topical use. US FDA approved product information. (2022) [cited August 28, 2024; https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215309s001lbl.pdf
Kubelis-López DE et al (2021) Updates and new medical treatments for vitiligo (review). Exp Ther Med 22(2):797
doi: 10.3892/etm.2021.10229
pubmed: 34093753
pmcid: 8170669
Seneschal J, Boniface K (2023) Vitiligo: current therapies and future treatments. Dermatol Pract Concept, 13(4s2)
Coondoo A et al (2014) Side-effects of topical steroids: a long overdue revisit. Indian Dermatol Online J 5(4):416–425
doi: 10.4103/2229-5178.142483
pubmed: 25396122
pmcid: 4228634
Bouceiro Mendes R, Alpalhão M, Filipe P (2022) UVB phototherapy in the treatment of vitiligo: state of the art and clinical perspectives. Photodermatol Photoimmunol Photomed 38(3):215–223
doi: 10.1111/phpp.12740
pubmed: 34626483
Post NF et al (2022) The use of lasers in vitiligo, an overview. J Eur Acad Dermatol Venereol 36(6):779–789
doi: 10.1111/jdv.18005
pubmed: 35176186
pmcid: 9314124
Rosmarin D, Soliman AM, Li C (2023) Real-world treatment patterns in patients with Vitiligo in the United States. Dermatol Ther (Heidelb) 13(9):2079–2091
doi: 10.1007/s13555-023-00983-3
pubmed: 37548877
Liu B et al (2021) Reciprocal regulation of interleukin-17A and interleukin-22 secretion through aryl hydrocarbon receptor activation in CD4(+) T cells of patients with vitiligo. Exp Ther Med 21(2):158
doi: 10.3892/etm.2020.9589
pubmed: 33456525
Napolitano M, Patruno C (2018) Aryl hydrocarbon receptor (AhR) a possible target for the treatment of skin disease. Med Hypotheses 116:96–100
doi: 10.1016/j.mehy.2018.05.001
pubmed: 29857917
Rekik R et al (2017) Aryl hydrocarbon receptor (AhR) transcription is decreased in skin of vitiligo patients. Int J Dermatol 56(12):1509–1512
doi: 10.1111/ijd.13761
pubmed: 28960282
Elder AJ, Patel P, Daveluy S (2024) Tapinarof, in StatPearls. StatPearls Publishing Copyright © 2024, StatPearls Publishing LLC.: Treasure Island (FL)
Chen Z et al (2023) Roflumilast enhances the melanogenesis and attenuates oxidative stress-triggered damage in melanocytes. J Dermatol Sci 110(2):44–52
doi: 10.1016/j.jdermsci.2023.04.001
pubmed: 37069030
Liu B, Xie Y, Wu Z (2020) Astragaloside IV enhances Melanogenesis via the AhR-Dependent AKT/GSK-3β/β-Catenin pathway in normal human epidermal melanocytes. Evid Based Complement Alternat Med 2020:p8838656
doi: 10.1155/2020/8838656
Majid I, Imran S, Batool S (2019) Apremilast is effective in controlling the progression of adult vitiligo: a case series. Dermatol Ther 32(4):e12923
doi: 10.1111/dth.12923
pubmed: 30977956
Prieto K, Duong JQ, Feldman SR (2024) Tapinarof cream for the topical treatment of plaque psoriasis in adults. Expert Rev Clin Immunol 20(4):327–337
doi: 10.1080/1744666X.2023.2296607
pubmed: 38117596
Li J et al (2024) The relationship between psoriasis and vitiligo: from a comprehensive study. Skin Res Technol 30(7):e13868
doi: 10.1111/srt.13868
pubmed: 39031921
pmcid: 11259540
Liu L et al (2023) Vitiligo responds to topical aryl hydrocarbon receptor agonist tapinarof (WBI-1001). JAAD case Rep 39:150–151
doi: 10.1016/j.jdcr.2023.06.051
pubmed: 37693929
pmcid: 10491801
Huff S.B., Gottwald L.D. (2017) Repigmentation of tenacious vitiligo on Apremilast. Case Rep Dermatol Med 2017:p2386234
Szczurko O et al (2011) Ginkgo biloba for the treatment of vitilgo vulgaris: an open label pilot clinical trial. BMC Complement Altern Med 11:21
doi: 10.1186/1472-6882-11-21
pubmed: 21406109
pmcid: 3065445
Parsad D, Pandhi R, Juneja A (2003) Effectiveness of oral Ginkgo biloba in treating limited, slowly spreading vitiligo. Clin Exp Dermatol 28(3):285–287
doi: 10.1046/j.1365-2230.2003.01207.x
pubmed: 12780716
Vogel CFA et al (2020) The aryl hydrocarbon receptor as a target of environmental stressors - implications for pollution mediated stress and inflammatory responses. Redox Biol 34:101530
doi: 10.1016/j.redox.2020.101530
pubmed: 32354640
pmcid: 7327980
Nguyen NT, Fisher DE (2019) MITF and UV responses in skin: from pigmentation to addiction. Pigment Cell Melanoma Res 32(2):224–236
doi: 10.1111/pcmr.12726
pubmed: 30019545
Zang D, Niu C, Aisa HA (2019) Amine derivatives of furocoumarin induce melanogenesis by activating Akt/GSK-3β/β-catenin signal pathway. Drug Des Devel Ther 13:623–632
doi: 10.2147/DDDT.S180960
pubmed: 30858693
pmcid: 6387609
Nakamura M et al (2013) Tobacco smoke-induced skin pigmentation is mediated by the aryl hydrocarbon receptor. Exp Dermatol 22(8):556–558
doi: 10.1111/exd.12170
pubmed: 23802610
Abbas S et al (2017) Aryl Hydrocarbon receptor activation contributes to Benzanthrone-Induced Hyperpigmentation via Modulation of Melanogenic Signaling Pathways. Chem Res Toxicol 30(2):625–634
doi: 10.1021/acs.chemrestox.6b00364
pubmed: 28029781
Fiorito S et al (2018) Natural oxyprenylated coumarins are modulators of melanogenesis. Eur J Med Chem 152:274–282
doi: 10.1016/j.ejmech.2018.04.051
pubmed: 29730190
Luecke S et al (2010) The aryl hydrocarbon receptor (AHR), a novel regulator of human melanogenesis. Pigment Cell Melanoma Res 23(6):828–833
doi: 10.1111/j.1755-148X.2010.00762.x
pubmed: 20973933
Krämer HJ et al (2005) Malassezin, a novel agonist of the aryl hydrocarbon receptor from the yeast Malassezia Furfur, induces apoptosis in primary human melanocytes. ChemBioChem 6(5):860–865
doi: 10.1002/cbic.200400247
pubmed: 15812864
Blauvelt A et al (2024) Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: a randomized, double-blinded, vehicle-controlled, phase 3 trial. J Am Acad Dermatol 90(5):986–993
doi: 10.1016/j.jaad.2023.12.065
pubmed: 38253129
Wang X et al (2019) Role of the aryl hydrocarbon receptor signaling pathway in promoting mitochondrial biogenesis against oxidative damage in human melanocytes. J Dermatol Sci 96(1):33–41
doi: 10.1016/j.jdermsci.2019.09.001
pubmed: 31543430
Strober B et al (2022) One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: results from the PSOARING 3 trial. J Am Acad Dermatol 87(4):800–806
doi: 10.1016/j.jaad.2022.06.1171
pubmed: 35772599
Lebwohl MG et al (2021) Phase 3 trials of tapinarof cream for Plaque Psoriasis. N Engl J Med 385(24):2219–2229
doi: 10.1056/NEJMoa2103629
pubmed: 34879448
Silverberg JI et al (2024) Tapinarof cream 1% once daily: significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials. J Am Acad Dermatol 91(3):457–465
doi: 10.1016/j.jaad.2024.05.023
pubmed: 38777187
Lebwohl MG et al (2020) Trial of Roflumilast Cream for Chronic Plaque Psoriasis. N Engl J Med 383(3):229–239
doi: 10.1056/NEJMoa2000073
pubmed: 32668113
Saeki H et al (2022) Difamilast ointment in adult patients with atopic dermatitis: a phase 3 randomized, double-blind, vehicle-controlled trial. J Am Acad Dermatol 86(3):607–614
doi: 10.1016/j.jaad.2021.10.027
pubmed: 34710557
Martín-Santiago A et al (2022) Safety Profile and Tolerability of Topical phosphodiesterase 4 inhibitors for the treatment of atopic dermatitis: a systematic review and Meta-analysis. Curr Ther Res Clin Exp 96:100679
doi: 10.1016/j.curtheres.2022.100679
pubmed: 35846836
pmcid: 9278032